Company intelligence / Profile preview

Diffusion Pharmaceuticals Inc.

Charlottesville, Virginia, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 2

Overview

Diffusion’s lead candidate trans sodium crocetinate (TSC) showed promising safety and tolerability in early trials for improving oxygenation in hypoxic tissues. In Phase II studies for glioblastoma multiforme, TSC combined with standard-of-care therapies suggested improved survival rates compared to standard therapy alone. The company received FDA guidance for a Phase III trial but paused further development following its merger with EIP Pharma.[6][9]

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: Small molecules[1][2][5]
Industry: Biotech

Drug pipeline

1 asset

trans sodium crocetinate

Phase 2

Indications: COVID-19, Acute stroke, Solid tumors, Glioblastoma multiforme, Peripheral artery disease

Beyond the preview

Go deeper on Diffusion Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diffusion Pharmaceuticals Inc..

Explore the full profile